{"resourceType": "EvidenceVariable", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"], "versionId": "5", "lastUpdated": "2025-09-14T18:30:51.295Z"}, "contained": [{"resourceType": "Group", "id": "variable-definition", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"]}, "membership": "conceptual", "characteristic": [{"code": {"text": "defined by CodeableConcept"}, "valueCodeableConcept": {"text": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM"}, "exclude": false, "timing": [{"text": "Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration"}]}]}], "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail", "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-variable-handling-not-specified", "display": "Evidence variable handling not specified"}]}}], "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "267231", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-secondaryOutcome-4", "assigner": {"display": "Computable Publishing LLC"}}], "title": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)", "status": "active", "description": "PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM.", "definition": {"reference": {"reference": "#variable-definition", "type": "Group"}}, "handling": "extension", "id": "267231", "url": "https://fevir.net/resources/EvidenceVariable/267231", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267231. Revised 2025-09-14. Available at: https://fevir.net/resources/EvidenceVariable/267231. Computable resource at: https://fevir.net/resources/EvidenceVariable/267231#json.", "name": "PK_Change_From_Baseline_in_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379"}